Dechao Jiao1, Kai Huang2, Ming Zhu1, Gang Wu1, Jianzhuang Ren1, Yanli Wang1, Xinwei Han3. 1. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. 2. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China. 3. Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. 13592583911@163.com.
Abstract
BACKGROUND: Whether unilateral or bilateral drainage should be performed for malignant hilar biliary obstruction remains a matter of debate. Although a Y-stent with a central wide-open mesh facilitates bilateral stent placement, it has its own limitations. AIM: This study aims to evaluate the feasibility and efficacy of a newly designed Y-configured bilateral self-expanding metallic stent (SEMS) for the treatment of hilar biliary obstruction. METHODS: In this retrospective study, 14 consecutive patients with unresectable malignant hilar biliary obstruction (Bismuth type II or higher), who underwent placement of a newly designed Y-configured bilateral SEMS for hilar biliary obstruction from April 2013 to March 2015, were included into this study. Data on technical success, clinical success, stent patency, complications and patient survival were collected. RESULTS: Technical and clinical success was 100 and 92.9 %, respectively. Mean serum bilirubin level was significantly decreased 1 month after stent placement (P < 0.01). Furthermore, two patients (14.3 %) had early complications (one patient had severe hemobilia and one patient had cholangitis), and two patients (14.3 %) had late complications (one patient had cholangitis and one patient had cholecystitis). During the mean follow-up period of 298 days (range 89-465 days), six patients (42.9 %) developed stent occlusion caused by tumor ingrowth or overgrowth (n = 5) and sludge (n = 1). Median stent patency and overall survival times were 281 days (95 % CI 175.9-386.1 days) and 381 days (95 % CI 291.4-470.6 days), respectively. CONCLUSION: The use of the newly designed Y-configured bilateral SEMS is feasible and effective for hilar biliary obstruction using port docking deployment.
BACKGROUND: Whether unilateral or bilateral drainage should be performed for malignant hilar biliary obstruction remains a matter of debate. Although a Y-stent with a central wide-open mesh facilitates bilateral stent placement, it has its own limitations. AIM: This study aims to evaluate the feasibility and efficacy of a newly designed Y-configured bilateral self-expanding metallic stent (SEMS) for the treatment of hilar biliary obstruction. METHODS: In this retrospective study, 14 consecutive patients with unresectable malignant hilar biliary obstruction (Bismuth type II or higher), who underwent placement of a newly designed Y-configured bilateral SEMS for hilar biliary obstruction from April 2013 to March 2015, were included into this study. Data on technical success, clinical success, stent patency, complications and patient survival were collected. RESULTS: Technical and clinical success was 100 and 92.9 %, respectively. Mean serum bilirubin level was significantly decreased 1 month after stent placement (P < 0.01). Furthermore, two patients (14.3 %) had early complications (one patient had severe hemobilia and one patient had cholangitis), and two patients (14.3 %) had late complications (one patient had cholangitis and one patient had cholecystitis). During the mean follow-up period of 298 days (range 89-465 days), six patients (42.9 %) developed stent occlusion caused by tumor ingrowth or overgrowth (n = 5) and sludge (n = 1). Median stent patency and overall survival times were 281 days (95 % CI 175.9-386.1 days) and 381 days (95 % CI 291.4-470.6 days), respectively. CONCLUSION: The use of the newly designed Y-configured bilateral SEMS is feasible and effective for hilar biliary obstruction using port docking deployment.
Authors: J-M Dumonceau; A Tringali; D Blero; J Devière; R Laugiers; D Heresbach; G Costamagna Journal: Endoscopy Date: 2012-02-01 Impact factor: 10.093
Authors: Jennifer Hsieh; Amar Thosani; Matthew Grunwald; Satish Nagula; Juan Carlos Bucobo; Jonathan M Buscaglia Journal: Hepatobiliary Surg Nutr Date: 2015-10 Impact factor: 7.293
Authors: Do Hyun Park; Sang Soo Lee; Jong Ho Moon; Hyun Jong Choi; Sang-Woo Cha; Jong Hyeok Kim; Dong-Wan Seo; Sung-Koo Lee; Sang-Heum Park; Moon-Sung Lee; Sun-Joo Kim; Myung-Hwan Kim Journal: Gastrointest Endosc Date: 2009-06 Impact factor: 9.427
Authors: Jung Hyun Lee; Dae Hwan Kang; Ji Young Kim; Sun Mi Lee; Do Hoon Kim; Chan Won Park; Hwal Suk Cho; Gwang Ha Kim; Tae Oh Kim; Jeong Heo; Geun Am Song; Mong Cho; Suk Kim; Chang Won Kim; Jun Woo Lee Journal: Gastrointest Endosc Date: 2007-08 Impact factor: 9.427